Objective: This study aims to analyze the distribution of positive human papillomavirus (HPV) infections among women of appropriate age in Beiliu City during cervical cancer screening in 2024, providing data support for subsequent public health interventions. Methods: A retrospective analysis was conducted on the HPV test results from January 1, 2024, to November 30, 2024, at Beiliu Maternal and Child Health Hospital. We statistically analyzed the positive rates of different HPV genotypes and the co-infection status of multiple genotypes. Results: A total of 7558 individuals were tested, with 1103 positive cases identified, resulting in a positivity rate of 14.59%. Among these, HPV type 52 had the highest positive rate, accounting for 18.47%. The co-infection analysis showed that there were 788 cases with single genotype positivity, 236 with double genotype positivity, and 58 with triple genotype positivity, while cases with multiple genotypes simultaneously positive were relatively rare. Conclusion: The HPV infection rate among women of appropriate age in Beiliu City is relatively high, especially for high-risk HPV types. To reduce the future incidence of cervical cancer, it is recommended to enhance health education and vaccination efforts for this population.
References
[1]
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., et al. (2020) Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis. The Lancet Global Health, 8, e191-e203. https://doi.org/10.1016/s2214-109x(19)30482-6
[2]
Wang, X., Li, M., Zhang, W., et al. (2020) Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis. Chinese Journal of Oncology, 42, 433-440. https://doi.org/10.3760/cma.j.cn112151-20191212-00292
[3]
Kahn, J.A., Harel, O., Burk, R.D., et al. (2021) HPV Vaccination and Cervical Cancer Screening: A Critical Review of the Literature. Journal of Adolescent Health, 68, 967-975.
[4]
Li, H., Zhang, W. and Wang, F. (2020) Current Status and Trends of Cervical Cancer Screening. Chinese Journal of Gynecologic Oncology, 25, 173-178.
[5]
Visioli, A., Bianchi, F., D’Aiuto, M., et al. (2023) Cervical Cancer Screening: New Perspectives and Challenges. Current Opinion in Obstetrics and Gynecology, 35, 123-130.
[6]
Zhao, Q. and Liu, J. (2021) Research Progress on the Impact of HPV Vaccination on Cervical Cancer Prevention. Chinese Medical Journal, 101, 1152-1156.
[7]
Saslow, D., Solomon, D., Lawson, H.W., et al. (2020) American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA: A Cancer Journal for Clinicians, 70, 389-401. https://doi.org/10.3322/caac.21514
[8]
Bruni, L., Diaz, M., Castellsagué, X., et al. (2020). Cervical Cancer Screening in Low-Resource Settings: Current Challenges and Future Directions. The Lancet Global Health, 8, e1450-e1451. https://doi.org/10.1016/S2214-109X(20)30373-3
[9]
Houghton, J., Decker, S.E., et al. (2021). Impact of COVID-19 on Breast and Cervical Cancer Screening in the United States. Cancer Control, 28. https://doi.org/10.1177/10732748211016560
[10]
Ginsburg, O., Shetty, P., et al. (2020). The Global Burden of Women’s Cancers: A Grand Challenge in Global Health. The Lancet, 395, 1007-1009. https://doi.org/10.1016/S0140-6736(20)30324-8
[11]
Moyer, V.A. (2021) Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. JAMA, 325, 1640-1646. https://doi.org/10.1001/jama.2021.4270
[12]
Smith, R.A., Andrews, K., et al. (2022) Cancer Screening in the United States, 2022: A Review. CA: A Cancer Journal for Clinicians, 72, 10-29.
[13]
Katalin, G., Szabo, A., et al. (2023) Screening for Cervical Cancer: A Systematic Review of the Literature. European Journal of Cancer, 173, 31-42.
[14]
Lee, C., Kim, S., Han, J., et al. (2021) Assessing the Implementation of Breast Cancer Screening Guidelines in Practice. BMC Health Services Research, 21, 1-10.
